Cap-Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target

Yan Jia, Vitaly Polunovsky, Peter B. Bitterman, Carston R. Wagner

Research output: Contribution to journalReview articlepeer-review

72 Scopus citations

Abstract

Cancer cells tend to be more highly dependent on cap-dependent translation than normal tissues. Thus, proteins involved in the initiation of cap-dependent translation have emerged as potential anti-cancer drug targets. Cap-dependent translation is initiated by the binding of the factor eIF4E to the cap domain of mRNA. Detailed x-ray crystal and NMR structures are available for eIF4E in association with cap-analogs, as well as domains of other initiation factors. This review will summarize efforts to design potential antagonist of eIF4E that could be used as new pharmacological tools and anti-cancer agents and. Insights drawn from these studies should aid in the design of future inhibitors of eIF4E dependent translation initiation.

Original languageEnglish (US)
Pages (from-to)786-814
Number of pages29
JournalMedicinal Research Reviews
Volume32
Issue number4
DOIs
StatePublished - Jul 1 2012

Keywords

  • Anticancer
  • EIF4E
  • Translation

Fingerprint Dive into the research topics of 'Cap-Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target'. Together they form a unique fingerprint.

Cite this